Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

21. Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial Full Text available with Trip Pro

Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial Denosumab (DNM) is a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL) that has been licensed for the treatment of different types of osteoporosis. However, the prospective data for the evaluation of DNM efficacy on transfusion-dependent thalassemia (TDT)-induced osteoporosis are rather limited. Thus, we (...) conducted a randomized, placebo-controlled, double-blind, phase 2b clinical trial to evaluate DNM in TDT osteoporosis. Patients were assigned to receive either 60 mg DNM (n = 32) or placebo (n = 31) subcutaneously on day 0 and 180 during a total of 12 months of follow-up. The percentage increase of L1-L4 bone mineral density was higher in the DNM group than the placebo group (5.92% ± 5.25% vs 2.92% ± 5.56%, respectively; P = .043), whereas the advantage of DNM regarding wrist bone mineral density

2018 Blood advances Controlled trial quality: predicted high

22. Osteoporosis

Osteoporosis Osteoporosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Osteoporosis Last reviewed: February 2019 Last updated: October 2018 Summary Asymptomatic until fracture occurs. Diagnosis based on history of prior fragility fracture or low bone mineral density, which is defined as a T-score ≤-2.5. Screening is based on individual risk factors, including female sex, maternal history of fragility fracture (...) /osteoporosis, older age, low body mass index (<20 to 25 kg/m²), body weight <58 kg, weight loss of >10% of body weight, androgen deprivation treatment (in males), aromatase inhibitor treatment (in females), corticosteroid use, tobacco use, and kidney stone disease. Fall prevention is first-line therapy. Bisphosphonates are first-line pharmacological therapy for postmenopausal women and men. In postmenopausal women, oestrogen is considered only for those at high risk for whom non-oestrogen medicines

2018 BMJ Best Practice

23. Osteoporosis

Osteoporosis Top results for osteoporosis - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for osteoporosis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

24. Osteoanabolic Agents for Osteoporosis Full Text available with Trip Pro

Osteoanabolic Agents for Osteoporosis Medications for osteoporosis are classified as either antiresorptive or anabolic. Whereas antiresorptive agents prevent bone resorption, anabolic agents promote new bone formation. Anabolics should be considered in individuals with severe osteoporosis, failure of alternative osteoporosis agents, intolerability or contraindications to other osteoporosis agents, and glucocorticoid-induced osteoporosis. There are currently two approved anabolic therapies

2018 Journal of the Endocrine Society

25. Osteoporosis

Osteoporosis Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

26. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. By 2020, approximately 12.3 million individuals in the United States older than 50 years are expected to have osteoporosis. Osteoporotic fractures, particularly hip fractures, are associated with limitations in ambulation, chronic pain and disability, loss of independence, and decreased quality of life, and 21% to 30% of patients who experience a hip fracture die within 1 year (...) . The prevalence of primary osteoporosis (ie, osteoporosis without underlying disease) increases with age and differs by race/ethnicity. With the aging of the US population, the potential preventable burden is likely to increase in future years.To update the 2011 US Preventive Services Task Force (USPSTF) recommendation on screening for osteoporosis.The USPSTF reviewed the evidence on screening for and treatment of osteoporotic fractures in men and women, as well as risk assessment tools, screening intervals

2018 JAMA

27. How Would You Manage This Patient With Osteoporosis?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. (Abstract)

How Would You Manage This Patient With Osteoporosis?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Osteoporosis is a skeletal disorder characterized by reduced bone strength that increases the risk for fracture. Approximately 10 million men and women in the United States have osteoporosis, and more than 2 million osteoporosis-related fractures occur annually. In 2016, the American Association of Clinical Endocrinologists issued the "Clinical Practice Guideline (...) for the Diagnosis and Treatment of Postmenopausal Osteoporosis," and in 2017, the American College of Physicians issued the guideline "Treatment of Low Bone Density or Osteoporosis to Prevent Fracture in Men and Women." Both guidelines agree that patients diagnosed with osteoporosis should be treated with an antiresorptive agent, such as alendronate, that has been shown to reduce hip and vertebral fractures. However, there is no consensus on how long patients with osteoporosis should be treated and whether bone

2018 Annals of Internal Medicine

28. Comparative assessment of fracture risk among osteoporosis and osteopenia patients: a cross-sectional study Full Text available with Trip Pro

Comparative assessment of fracture risk among osteoporosis and osteopenia patients: a cross-sectional study Both osteoporosis and osteopenia remain worldwide public health concerns. They both lead to bone fractures, which can lead to disability and burden on those who are afflicted.To assess and compare fracture risk between these two groups of patients.Our cross-sectional study included 82 patients (46 with osteoporosis and 36 with osteopenia) with an average age of 63±9.33 years, who received (...) treatment at the Clinic for Medical Rehabilitation, Clinical Center of Vojvodina in Novi Sad, Serbia. The assessment of the fracture risk was executed by applying the Fracture Assessment Risk (FRAX) index (an algorithm developed by the World Health Organization) based on clinical fracture risks or combination of clinical fracture risks and bone mineral density.Patients with osteoporosis had significantly higher risk of major fracture compared to patients with osteopenia (p<0.01). Results from FRAX index

2018 Open access rheumatology : research and reviews

29. Prevention and treatment of osteoporosis in women

Prevention and treatment of osteoporosis in women Prevention and treatment of osteoporosis in women | British Menopause Society Search for: Summary consensus statement Prevention and treatment of osteoporosis in women Prevention and treatment of osteoporosis in women 2018-11-09T17:16:44+01:00 Summary The British Menopause Society Council aims to aid health professionals to inform and advise women about post reproductive health. Osteoporosis affects 1 in 3 women. This guidance regarding (...) oestrogen and non oestrogen based treatments for osteoporosis responds to the controversies about the benefits and risks of individual agents. Treatment choice should be based on up to date evidence based information and targeted to individual women’s needs. Summary practice points HRT reduces the risk of both spine and hip as well as other osteoporotic fractures. Oestrogen remains the treatment of choice for osteoporosis prevention in menopausal women, and especially in those with premature ovarian

2018 British Menopause Society

30. Osteoporosis

Osteoporosis Osteoporosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Osteoporosis Last reviewed: February 2019 Last updated: October 2018 Summary Asymptomatic until fracture occurs. Diagnosis based on history of prior fragility fracture or low bone mineral density, which is defined as a T-score ≤-2.5. Screening is based on individual risk factors, including female sex, maternal history of fragility fracture (...) /osteoporosis, older age, low body mass index (<20 to 25 kg/m²), body weight <58 kg, weight loss of >10% of body weight, androgen deprivation treatment (in males), aromatase inhibitor treatment (in females), corticosteroid use, tobacco use, and kidney stone disease. Fall prevention is first-line therapy. Bisphosphonates are first-line pharmacological therapy for postmenopausal women and men. In postmenopausal women, oestrogen is considered only for those at high risk for whom non-oestrogen medicines

2018 BMJ Best Practice

31. Interim Clinical Commissioning Policy Statement: Teriparatide for Osteoporosis in Men (Adults)

Interim Clinical Commissioning Policy Statement: Teriparatide for Osteoporosis in Men (Adults) NHS England » Interim Clinical Commissioning Policy Statement: Teriparatide for Osteoporosis in Men (Adults) Search Search Menu Interim Clinical Commissioning Policy Statement: Teriparatide for Osteoporosis in Men (Adults) Document first published: 6 July 2018 Page updated: 6 July 2018 Topic: , Publication type: This policy document outlines the arrangements for funding of treatment for Osteoporosis

2018 NHS England

32. Osteoporosis — identification and management in primary care

Osteoporosis — identification and management in primary care '); } else { document.write(' '); } ACE | Osteoporosis — identification and management in primary care Search > > Osteoporosis — identification and management in primary care - Osteoporosis — identification and management in primary care Published on 7 November 2018 This Appropriate Care Guide (ACG) highlights the importance of early identification of patients at risk of osteoporosis or fragility fracture. Guidance is provided on risk (...) assessment, correct diagnosis, and management considerations. It also includes a supplementary guide on treatment options and bisphosphonates treatment monitoring. Download the PDF below to access the full ACG. Key Messages 1. Assess osteoporosis risk in post-menopausal women, and men 65 years and older. 2. Diagnose osteoporosis in patients with a fragility fracture or DXA BMD T-score ≤ -2.5. 3. Treat patients diagnosed with osteoporosis or patients with osteopaenia and high fracture risk. 4. Refer

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

33. Osteoporosis to Prevent Fractures: Screening

Osteoporosis to Prevent Fractures: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Women 65 years and older The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older. B Postmenopausal women younger than 65 years at increased risk of osteoporosis The USPSTF recommends screening for osteoporosis with bone measurement testing (...) to prevent osteoporotic fractures in postmenopausal women younger than 65 years who are at increased risk of osteoporosis, as determined by a formal clinical risk assessment tool. See the Clinical Considerations section for information on risk assessment. B Men The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for osteoporosis to prevent osteoporotic fractures in men. See the Clinical Considerations section for suggestions for practice

2018 U.S. Preventive Services Task Force

34. Cone Beam Computed Tomography Can be Used as an Auxiliary Diagnostic Tool for Osteoporosis

Cone Beam Computed Tomography Can be Used as an Auxiliary Diagnostic Tool for Osteoporosis UTCAT3302, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Cone Beam Computed Tomography Can be Used as an Auxiliary Diagnostic Tool for Osteoporosis Clinical Question Can cone beam computed tomography be considered a helpful tool in predicting osteoporosis? Clinical Bottom Line Cone beam computed tomography imaging (...) is a promising technique to predict osteoporosis. For patients who have osteoporosis, CBCT radiodensity can be a predictor of low bone mineral density (BMD). Dentists can use this as a tool to help in early diagnosis and referral of the patient to a physician to manage the case before deterioration. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Guerra/2017 6 studies, 220 patients Systematic review

2017 UTHSCSA Dental School CAT Library

35. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. (Abstract)

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. No clinical trials have compared osteoporosis drugs with incident fractures as the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate in patients with severe osteoporosis.In this double-blind, double-dummy trial, we enrolled post-menopausal women with at least two moderate (...) in the risedronate group (hazard ratio 0·48, 95% CI 0·32-0·74; p=0·0009). Non-vertebral fragility fractures occurred in 25 (4·0%) patients in the teriparatide group and 38 (6·1%) in the risedronate group (hazard ratio 0·66; 95% CI 0·39-1·10; p=0·10).Among post-menopausal women with severe osteoporosis, the risk of new vertebral and clinical fractures is significantly lower in patients receiving teriparatide than in those receiving risedronate.Lilly.Copyright © 2018 Elsevier Ltd. All rights reserved.

2017 Lancet Controlled trial quality: predicted high

36. Leveraging Scarce Resources With Bone Health TeleECHO to Improve the Care of Osteoporosis Full Text available with Trip Pro

Leveraging Scarce Resources With Bone Health TeleECHO to Improve the Care of Osteoporosis Osteoporosis is a common condition with serious consequences because of fractures. Despite availability of treatments to reduce fracture risk, there is a large osteoporosis treatment gap that has reached crisis proportions. There are too few specialists to provide services for patients who need them. Bone Health Extension for Community Health Care Outcomes (TeleECHO) is a strategy using real-time ongoing (...) -confidence in 20 domains of osteoporosis care showed substantial improvement with the ECHO intervention (P = 0.005). Bone Health TeleECHO can contribute to mitigating the crisis in osteoporosis care by leveraging scarce resources, providing motivated practitioners with skills to provide better skeletal health care, closer to home, with greater convenience, and lower cost than referral to a specialty center. Bone Health TeleECHO can be replicated in any location worldwide to reach anyone with Internet

2017 Journal of the Endocrine Society

37. Prevention of osteoporosis in female students based on the Orem self-care model Full Text available with Trip Pro

Prevention of osteoporosis in female students based on the Orem self-care model The World Health Organization has introduced osteoporosis as the fourth main enemy of mankind. Self care has served as a new trend in health care.Educational intervention for osteoporosis related preventive self care in female university students using the Orem model.This study is a controlled filed trial, carried out with female students of Islamic Azad University, Shahrekord Branch, Iran, from October 28, 2014 (...) to November 15, 2016. Two-stage random stratified sampling was performed and the data were collected through a validated questionnaire developed by the researcher for osteoporosis preventive self-care based on the Orem model. The intervention group received education about osteoporosis preventive self-care through two months training, as per the dimensions in the Orem model. For statistical analysis, independent-samples t-test and paired t-test were used in SPSS version 23.As revealed, mean scores

2017 Electronic physician

38. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. Full Text available with Trip Pro

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption.We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open-label alendronate (...) observed more often with romosozumab than with alendronate (50 of 2040 patients [2.5%] vs. 38 of 2014 patients [1.9%]). During the open-label alendronate period, adjudicated events of osteonecrosis of the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral fracture (2 events and 4 events, respectively) were observed.In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment for 12 months followed

2017 NEJM Controlled trial quality: uncertain

39. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis Full Text available with Trip Pro

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP).We conducted a systematic review to synthesize the evidence for the benefits and harms of GIOP prevention and treatment options. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence. We used a group (...) GC users.Because of limited evidence regarding the benefits and harms of interventions in GC users, most recommendations in this guideline are conditional (uncertain balance between benefits and harms). Recommendations include treating only with calcium and vitamin D in adults at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication (oral bisphosphonate preferred) in adults at moderate-to-high fracture risk, continuing calcium plus vitamin D

2017 EvidenceUpdates

40. Bisphosphonates for treating osteoporosis

Bisphosphonates for treating osteoporosis Bisphosphonates for treating Bisphosphonates for treating osteoporosis osteoporosis T echnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence (...) an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Bisphosphonates for treating osteoporosis (TA464) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 25Contents Contents 1 Recommendations 4 2 The technologies 7 3 Committee discussion 9 Nature of the condition 9 Clinical management of the condition 9 Assessing

2017 National Institute for Health and Clinical Excellence - Technology Appraisals